16.64
price up icon0.24%   0.04
after-market アフターアワーズ: 16.41 -0.23 -1.38%
loading
前日終値:
$16.60
開ける:
$16.66
24時間の取引高:
349.32K
Relative Volume:
0.58
時価総額:
$856.84M
収益:
$107.46M
当期純損益:
$105.90M
株価収益率:
8.2067
EPS:
2.0276
ネットキャッシュフロー:
$238.50M
1週間 パフォーマンス:
+0.24%
1か月 パフォーマンス:
+20.75%
6か月 パフォーマンス:
+19.71%
1年 パフォーマンス:
+92.82%
1日の値動き範囲:
Value
$16.40
$16.80
1週間の範囲:
Value
$16.21
$16.99
52週間の値動き範囲:
Value
$8.33
$21.03

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name
名前
Theravance Biopharma Inc
Name
セクター
Healthcare (1112)
Name
電話
650-808-6000
Name
住所
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Name
職員
90
Name
Twitter
Name
次回の収益日
2026-03-25
Name
最新のSEC提出書
Name
TBPH's Discussions on Twitter

Compare TBPH vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
TBPH icon
TBPH
Theravance Biopharma Inc
16.64 854.78M 107.46M 105.90M 238.50M 2.0276
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 113.01B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 51.51B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 45.29B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 34.41B 5.36B 287.73M 924.18M 2.5229

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-05 ダウングレード Oppenheimer Outperform → Perform
2026-03-04 ダウングレード B. Riley Securities Buy → Neutral
2025-12-03 開始されました Oppenheimer Outperform
2025-09-12 開始されました B. Riley Securities Buy
2024-08-06 ダウングレード Leerink Partners Outperform → Market Perform
2024-04-12 開始されました BTIG Research Buy
2024-01-08 ダウングレード Evercore ISI Outperform → In-line
2022-05-23 開始されました SVB Leerink Outperform
2021-11-05 アップグレード JP Morgan Underweight → Neutral
2021-09-15 ダウングレード JP Morgan Overweight → Underweight
2021-08-25 ダウングレード Morgan Stanley Overweight → Underweight
2021-08-24 ダウングレード Cowen Outperform → Market Perform
2020-10-14 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-07-07 開始されました JP Morgan Overweight
2020-06-15 開始されました Morgan Stanley Equal-Weight
2020-05-13 開始されました Cowen Outperform
2020-01-08 繰り返されました H.C. Wainwright Buy
2019-11-06 アップグレード Robert W. Baird Underperform → Neutral
2019-10-29 開始されました H.C. Wainwright Buy
2018-03-29 再開されました Piper Jaffray Overweight
2017-08-17 開始されました Evercore ISI Outperform
2017-06-16 開始されました Cantor Fitzgerald Overweight
2017-05-11 繰り返されました Needham Buy
2016-12-21 開始されました Needham Buy
2016-11-03 開始されました Piper Jaffray Overweight
2016-10-12 ダウングレード Robert W. Baird Neutral → Underperform
2016-08-03 ダウングレード BofA/Merrill Neutral → Underperform
2016-06-20 開始されました Guggenheim Buy
2016-06-20 繰り返されました Leerink Partners Outperform
2016-05-12 開始されました Leerink Partners Outperform
2016-05-05 ダウングレード BofA/Merrill Buy → Neutral
2015-02-03 アップグレード Robert W. Baird Underperform → Neutral
すべてを表示

Theravance Biopharma Inc (TBPH) 最新ニュース

pulisher
02:34 AM

Bronstein, Gewirtz & Grossman, LLC Encourages Theravance Biopharma, Inc. (TBPH) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

02:34 AM
pulisher
Apr 14, 2026

Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49 - MSN

Apr 14, 2026
pulisher
Apr 14, 2026

2026-04-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Theravance Biopharma, Inc. (TBPH) and Encourages Investors to Learn More About the Investigation | NDAQ:TBPH | Press Release - Stockhouse

Apr 14, 2026
pulisher
Apr 13, 2026

Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewir - The National Law Review

Apr 13, 2026
pulisher
Apr 13, 2026

Risk Report: Is Theravance Biopharma Inc a cyclical or defensive stockPortfolio Return Summary & Verified Chart Pattern Signals - baoquankhu1.vn

Apr 13, 2026
pulisher
Apr 12, 2026

2026-04-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Theravance Biopharma, Inc. (TBPH) And Encourages Stockholders to Reach Out | NDAQ:TBPH | Press Release - Stockhouse

Apr 12, 2026
pulisher
Apr 09, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc.TBPH - PR Newswire

Apr 09, 2026
pulisher
Apr 09, 2026

Theravance's Q4 earnings and revenues miss estimates - MSN

Apr 09, 2026
pulisher
Apr 08, 2026

TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

Apr 08, 2026
pulisher
Apr 08, 2026

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Theravance Biopharma (TBPH) - The Globe and Mail

Apr 08, 2026
pulisher
Apr 07, 2026

TBPH: B. Riley Securities Raises Price Target to $17.00, Maintai - GuruFocus

Apr 07, 2026
pulisher
Apr 07, 2026

B. Riley Raises Price Target on Theravance Biopharma to $17 From $14, Keeps Neutral Rating - marketscreener.com

Apr 07, 2026
pulisher
Apr 06, 2026

Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget

Apr 06, 2026
pulisher
Apr 06, 2026

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research

Apr 06, 2026
pulisher
Apr 06, 2026

Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat

Apr 06, 2026
pulisher
Apr 05, 2026

JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH - marketbeat.com

Apr 05, 2026
pulisher
Apr 03, 2026

Theravance Biopharma (TBPH) CEO awarded 75,000 Ordinary Shares - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Theravance Biopharma (TBPH) CFO receives 37,500-share equity grant in Form 4 - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Theravance Biopharma (TBPH) SVP receives 37,500-share equity grant - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Theravance Biopharma (TBPH) SVP awarded 18,750 shares in Form 4 filing - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com

Apr 03, 2026
pulisher
Apr 02, 2026

TBPH PE Ratio & Valuation, Is TBPH Overvalued - Intellectia AI

Apr 02, 2026
pulisher
Apr 01, 2026

How Theravance Biopharma Inc. (TBPH) Affects Rotational Strategy Timing - Stock Traders Daily

Apr 01, 2026
pulisher
Apr 01, 2026

Tudor Investment Corp ET AL Decreases Stake in Theravance Biopharma, Inc. $TBPH - MarketBeat

Apr 01, 2026
pulisher
Mar 31, 2026

Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure - Markets Mojo

Mar 31, 2026
pulisher
Mar 31, 2026

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 31, 2026
pulisher
Mar 30, 2026

Big Picture: Can Theravance Biopharma Inc sustain its profitabilityLayoff News & Daily Profit Focused Screening - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

Theravance Secures Long-Term YUPELRI Patent Litigation Settlement - TipRanks

Mar 30, 2026
pulisher
Mar 30, 2026

Theravance Biopharma Inc. (TBPH) has disclosed that a settlement agreement has been filed with the U.S. Securities and Exchange Commission (SEC), and is currently under review by the Department of Justice and the Federal Trade Commission. - Bitget

Mar 30, 2026
pulisher
Mar 30, 2026

Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement - Stock Titan

Mar 30, 2026
pulisher
Mar 29, 2026

Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat

Mar 29, 2026
pulisher
Mar 28, 2026

Theravance Biopharma SEC Filing: Exhibits, Documents, and XBRL Taxonomy Reference Table - Minichart

Mar 28, 2026
pulisher
Mar 26, 2026

TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP - GlobeNewswire

Mar 26, 2026
pulisher
Mar 25, 2026

Weiss Asset Management (TBPH) details 7.46M-share, 14.5% Theravance Biopharma stake - Stock Titan

Mar 25, 2026
pulisher
Mar 25, 2026

Theravance drops rare disease drug after late-stage trial setback - MSN

Mar 25, 2026
pulisher
Mar 23, 2026

Theravance Biopharma (NASDAQ:TBPH) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

TBPH: Today's Rating Maintained by TD Cowen with Raised Price Ta - GuruFocus

Mar 23, 2026
pulisher
Mar 23, 2026

TD Cowen raises Theravance Biopharma stock price target on cash flow focus - Investing.com Canada

Mar 23, 2026
pulisher
Mar 23, 2026

Theravance Biopharma 2025 Annual Report: YUPELRI Commercialization, Strategic Review, and Organizational Restructuring - Minichart

Mar 23, 2026
pulisher
Mar 23, 2026

Theravance Biopharma 2025 10-K: $107.5M Revenue, $105.9M Net Income - tradingview.com

Mar 23, 2026
pulisher
Mar 23, 2026

Theravance Biopharma (NASDAQ: TBPH) restructures after ampreloxetine flop and royalty sale - Stock Titan

Mar 23, 2026
pulisher
Mar 21, 2026

Here's why Theravance Biopharma (TBPH) is a strong growth stock - MSN

Mar 21, 2026
pulisher
Mar 21, 2026

(TBPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Mar 21, 2026
pulisher
Mar 21, 2026

Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research - MarketBeat

Mar 21, 2026
pulisher
Mar 21, 2026

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen - MarketBeat

Mar 21, 2026
pulisher
Mar 20, 2026

Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView

Mar 20, 2026

Theravance Biopharma Inc (TBPH) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
大文字化:     |  ボリューム (24 時間):